Shattuck Labs to Participate in Upcoming December Investor Conferences
Shattuck Labs (NASDAQ: STTK) announced management will participate in multiple investor conferences in December 2025. CEO Taylor Schreiber, M.D., Ph.D. will present at the Piper Sandler 37th Annual Healthcare Conference on Dec 2, 2025 at 10:10 AM ET in New York and will take part in a fireside chat at the Evercore ISI 8th Annual HealthCONx Conference on Dec 4, 2025 at 8:20 AM ET in Coral Gables, plus one-on-one meetings on Dec 3–4. Webcast links will be provided and replays will be available on the company’s Events and Presentations page for up to 30 days after each presentation.
Shattuck Labs (NASDAQ: STTK) ha annunciato che la direzione parteciperà a molte conferenze per investitori nel dicembre 2025. Il CEO Taylor Schreiber, M.D., Ph.D. terrà una presentazione al Piper Sandler 37th Annual Healthcare Conference il 2 dicembre 2025 alle 10:10 AM ET a New York e parteciperà a un fireside chat alla Evercore ISI 8th Annual HealthCONx Conference il 4 dicembre 2025 alle 8:20 AM ET a Coral Gables, oltre a incontri one-on-one il 3-4 dicembre. Verranno forniti link webcast e le repliche saranno disponibili sulla pagina Eventi e Presentazioni della società per un massimo di 30 giorni dopo ciascuna presentazione.
Shattuck Labs (NASDAQ: STTK) anunció que la dirección participará en varias conferencias para inversores en diciembre de 2025. El CEO Taylor Schreiber, M.D., Ph.D. presentará en la Piper Sandler 37th Annual Healthcare Conference el 2 de diciembre de 2025 a las 10:10 a. m. ET en Nueva York y formará parte de una charla junto a una chimenea en la Evercore ISI 8th Annual HealthCONx Conference el 4 de diciembre de 2025 a las 8:20 a. m. ET en Coral Gables, además de reuniones uno a uno los días 3 y 4 de diciembre. Se proporcionarán enlaces de webcast y las repeticiones estarán disponibles en la página de Eventos y Presentaciones de la empresa hasta 30 días después de cada presentación.
Shattuck Labs (NASDAQ: STTK)는 경영진이 2025년 12월에 여러 투자자 컨퍼런스에 참가할 것이라고 발표했습니다. CEO Taylor Schreiber, M.D., Ph.D.가 뉴욕에서 열리는 Piper Sandler 37th Annual Healthcare Conference에서 2025년 12월 2일 동부표준시 10:10 AM에 발표하고 Dec 4, 2025 at 8:20 AM ET에 Coral Gables에서 열리는 Evercore ISI 8th Annual HealthCONx Conference의 fireside chat에 참여하며 12월 3~4일에 일대일 미팅을 가질 예정입니다. 웹캐스트 링크가 제공되며 각 발표 후 최대 30일간 회사의 이벤트 및 발표 페이지에서 재방송을 이용할 수 있습니다.
Shattuck Labs (NASDAQ : STTK) a annoncé que la direction participera à plusieurs conférences d'investisseurs en décembre 2025. Le PDG Taylor Schreiber, M.D., Ph.D. présentera lors de la Piper Sandler 37th Annual Healthcare Conference le 2 décembre 2025 à 10:10 AM ET à New York et participera à une discussion autour du feu lors de l'Evercore ISI 8th Annual HealthCONx Conference le 4 décembre 2025 à 8:20 AM ET à Coral Gables, ainsi que des rendez-vous en tête-à-tête les 3 et 4 décembre. Des liens Webcast seront fournis et les rediffusions seront disponibles sur la page Événements et Présentations de l'entreprise jusqu'à 30 jours après chaque présentation.
Shattuck Labs (NASDAQ: STTK) gab bekannt, dass das Management an mehreren Investorenkonferenzen im Dezember 2025 teilnehmen wird. CEO Taylor Schreiber, M.D., Ph.D. wird beim Piper Sandler 37th Annual Healthcare Conference am 2. Dezember 2025 um 10:10 Uhr ET in New York eine Präsentation halten und an einem Fireside-Chat bei der Evercore ISI 8th Annual HealthCONx Conference am 4. Dezember 2025 um 8:20 Uhr ET in Coral Gables teilnehmen, außerdem finden One-on-One-Meetings am 3.–4. Dezember statt. Webcast-Links werden bereitgestellt und Wiederholungen stehen auf der Seite des Unternehmens Events and Presentations bis zu 30 Tagen nach jeder Präsentation zur Verfügung.
Shattuck Labs (NASDAQ: STTK) أعلن أن الإدارة ستشارك في عدة مؤتمرات للمستثمرين في ديسمبر 2025. سيقدم المدير التنفيذي Taylor Schreiber, M.D., Ph.D. عرضاً خلال Piper Sandler 37th Annual Healthcare Conference في 2 ديسمبر 2025 الساعة 10:10 صباحاً بتوقيت شرق الولايات المتحدة في نيويورك وسيرتاد دردشة حول المدفأة في Evercore ISI 8th Annual HealthCONx Conference في 4 ديسمبر 2025 الساعة 8:20 صباحاً بتوقيت شرق الولايات المتحدة في كورال جيبلس، إضافة إلى اجتماعات فردية في 3-4 ديسمبر. ستُقدَّم روابط البث عبر الويب وستكون الإعادة متاحة في صفحة الأحداث والعروض الخاصة بالشركة حتى 30 يوماً بعد كل عرض.
- None.
- None.
AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that Company management will participate in multiple investor conferences in December 2025.
Conference Details
Conference: Piper Sandler 37th Annual Healthcare Conference
Format: Presentation and one-on-one meetings
Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer
Presentation Date: Dec 2, 2025
Time: 10:10 AM EST
Location: New York, NY
Webcast link: HERE
Conference: Evercore ISI 8th Annual HealthCONx Conference
Format: Fireside chat with Umer Raffat and Jonathan Miller, Ph.D. and one-on-one meetings (Dec 3-4)
Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer
Fireside Chat Date: Dec 4, 2025
Time: 8:20 AM EST
Location: Coral Gables, FL
Webcast link: HERE
A replay of the presentations from the Piper Sandler 37th Annual Healthcare Conference and the Evercore ISI 8th Annual HealthCONx Conference will be available on the Events and Presentations section of the Company’s website. A replay of the webcasts will remain archived for up to 30 days following the presentation date.
About SL-325
SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck’s preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. SL-325 is a fully Fc-silenced humanized immunoglobin G monoclonal antibody with a favorable safety profile in non-human primates, currently being evaluated in a Phase 1 clinical trial.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a clinical-stage biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor & Media Contact:
Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com